Bertin Pharma

Montigny-le-Bretonneux, France

Bertin Pharma

Montigny-le-Bretonneux, France

Time filter

Source Type

ONCODESIGN (Paris:ALONC) (FR0011766229 - ALONC), société biotechnologique au service de l’industrie pharmaceutique pour la découverte de nouvelles molécules thérapeutiques contre les cancers et autres maladies graves sans traitement efficace connu, annonce être entrée en phase de négociation exclusive pour l’acquisition des activités de services en Métabolisme, Pharmaco-cinétique, Bioanalyse et Médecine Translationnelle de Bertin Pharma. Ces activités dans les domaines de l’immunologie et de l’infectiologie, viendraient compléter idéalement l’offre actuelle de services du groupe Oncodesign. Créée il y a plus de 20 ans par le Dr. Philippe Genne, PDG et actionnaire principal, Oncodesign est une entreprise biotechnologique qui maximise les chances de succès de l’industrie pharmaceutique pour découvrir de nouvelles molécules thérapeutiques contre les cancers et autres maladies graves sans traitement efficace connu. Fort d’une expérience unique acquise auprès de plus de 600 clients, dont les plus grandes entreprises pharmaceutiques du monde, et s’appuyant sur une plateforme technologique complète, alliant chimie médicinale, pharmacologie et imagerie médicale de pointe, Oncodesign est en mesure de prédire et d’identifier, très en amont, pour chaque molécule son utilité thérapeutique et son potentiel à devenir un médicament efficace. Appliquée aux inhibiteurs de kinases, des molécules qui représentent un marché estimé à plus de 46 milliards de dollars en 2016 et près de 25% des investissements en R&D de l’industrie pharmaceutique, la technologie d’Oncodesign a déjà permis de cibler plusieurs molécules d’intérêts à fort potentiel thérapeutique, en oncologie et hors-oncologie, et de signer des partenariats avec des groupes pharmaceutiques tels que Bristol-Myers Squibb et UCB. Basée à Dijon, au cœur du pôle universitaire et hospitalier et au sein du cluster de Paris-Saclay, Oncodesign compte 165 collaborateurs et dispose de filiales au Canada et aux États-Unis.


ONCODESIGN (Paris:ALONC) (FR0011766229 - ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, has announced the opening of a period of exclusive negotiations to acquire Bertin Pharma's service businesses in Metabolism, Pharmacokinetics, Bio-analysis and Translational Medicine. These activities in the fields of immunology and infectiology will be an ideal fit with Oncodesign group's current service offering. The business portfolio under discussion has some 48 employees, with 2016 revenue of €5.3 million. It complements Oncodesign in many technological and regulatory areas and would contribute to the acceleration of Oncodesign group's 2017-2020 strategic plan for its service business. This project, which has been the subject of an information and consultation process with employee representative bodies, could be completed in the summer of 2017. At present it is not certain that any agreement will be reached nor that the transaction will be completed. No further comment will be made until an agreement is finalized. Founded over 20 years ago by Dr Philippe Genne, the Company’s CEO and Chairman, Oncodesign is a biotechnology company that maximises the pharmaceutical industry’s chances of success in discovering new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment. With its unique experience acquired by working with more than 600 clients, including the world’s largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, advanced animal modelling and medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over $46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB. Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster, Oncodesign has 165 employees and subsidiaries in Canada and the USA.


Marvalin C.,Bertin Pharma | Azerad R.,Bertin Pharma | Azerad R.,University of Paris Descartes
Journal of Molecular Catalysis B: Enzymatic | Year: 2011

In a typical series of experiments, several polyphenol O-β-d- glucuronides (including human metabolites) deriving from two flavonoids (naringenin, quercetin) and several stilbenoids (trans-resveratrol, rhapontigenin, deoxyrhapontigenin) have been obtained from the aglycones or their natural glycosides (Naringenin-7-O-glucoside, rutin, piceid, rhapontin or deoxyrhapontin), in a one step biotransformation and in moderate to high yields by incubation with a Streptomyces sp. strain M52104. Regioselectively glucuronidated products have been separated by chromatographic methods, then extensively characterized by MS and NMR. In all cases glucuronidation is β-stereospecific, but not completely regioselective. When present, the 4′(para)-hydroxyl group is generally favoured, then the 7-OH-group of flavonoids (corresponding to the 3-OH of stilbenoids). Several pure O-β-d-glucuronidated derivatives, commercially not available, have been prepared in high purity by this method. © 2011 Elsevier B.V. All Rights Reserved.


Delhanty P.J.D.,Erasmus MC | Huisman M.,Erasmus MC | Julien M.,Alizé Pharma | Mouchain K.,Bertin Pharma | And 4 more authors.
Clinical Endocrinology | Year: 2015

Context: The acylated/unacylated ghrelin (AG/UAG) ratio has been reported to range from 0.02 to 0.3, suggesting biologically relevant independent regulation of each ghrelin isoform. However, AG is deacylated to UAG by esterases in blood samples, and esterase inhibition is critical for their accurate measurement. Our hypothesis is that at least part of the variation in reported AG and UAG values is due to inconsistent sample preparation. Design: A non-interventional study. Quantification with two different, commercially available, ELISA formats of AG and UAG in venous plasma stabilized or not with 4-(2-aminoethyl) benzenesulphonyl fluoride (AEBSF) and stored for 0-6 months at -20 or -80 °C. Participants: Healthy, non-obese, adults (n = 8; 4 women), age 26-42 yrs, after an overnight fast. Measurements: AG and UAG stability following different methods of sample treatment and storage. Results: Non-AEBSF plasma contained low AG and high UAG (>270 pg/ml) indicating rapid conversion of AG to UAG. However, AEBSF plasma, stored at -80 °C and measured at 0, 1, 3 and 6 months contained AG and UAG ranges of 12-350 and 17-170 pg/ml, respectively. Mean (SEM) AG/UAG ratios were 1.7(0.3), 1.2(0.2), 1.5(0.3) and 1.8(0.5) at each time point with no significant effect of storage period. Conclusions: AG and UAG levels measured in AEBSF-stabilized plasma indicate that the AG/UAG ratio is markedly higher than previously described and that UAG is a physiological component of the circulation. This highlights the importance of immediately stabilizing blood samples on collection for determination of both AG and UAG concentrations and provides a valuable tool for their measurement in physiological and interventional studies. © 2014 John Wiley & Sons Ltd.


Marvalin C.,Bertin Pharma | Azerad R.,Bertin Pharma | Azerad R.,University of Paris Descartes
Xenobiotica | Year: 2011

The production in multimilligram amounts of 4- and 5-hydroxylated metabolites of (R)- or (S)-propranolol by biotransformation with two fungal strains, an Absidia sp. M50002 and a Cunninghamella sp. M50036, was carried out, starting from either the racemic drug or pure enantiomers. While both enantiomers of propranolol were hydroxylated in the 5-position by incubation with strain M50002, the strain M50036 operated a chiral discrimination, resulting in the exclusive formation of the 4-hydroxy-(R)-enantiomer. In addition, a Streptomyces sp. strain M52104, isolated from a soil sample, was selected for the high-yield regioselective β-glucuronidation of propranolol and its 4- and 5-hydroxylated derivatives. NMR and mass spectroscopic data have been extensively used for the unambiguous characterization of 4- and 5-hydroxylated and glucuronidated derivatives, all of them corresponding to the major animal and human metabolites of propranolol, a typical substrate of CYP2D6. © 2011 Informa UK, Ltd.


Trademark
Bertin Pharma | Date: 2013-06-04

Chemical products for use in science, namely, reagents for use with tandem mass spectrometry; diagnostic preparations for scientific purposes for use with tandem mass spectrometry. Chemical or biological products, namely, reagents designed for medical science, diagnostic products for medical purposes, namely, reagents; substances and reagents for biological purposes, namely, assay reagents for the analysis of body fluids, tissues, cells or organs. Pharmaceutical research and development services, scientific studies and diagnostics in the field of life sciences; technical research in the field of life sciences; chemical analysis; chemical research; biological research; subcontracting support services in connection with research and development, namely, scientific research for medical purposes, pharmaceutical research and development services, and diagnostic and scientific research in the field of life sciences.


„Wir sind froh, eine Einigung mit Bertin Pharma über die Expansion unseres Vertriebsnetzwerks in Europa erzielt zu haben. Wir freuen uns auf die Arbeit mit Patrick und seinem Team, um das Assay-Portfolio von INDIGO zu den Kunden in der ganzen Region zu bringen“, so Fred Marroni, CEO – INDIGO Biosciences.


News Article | November 15, 2016
Site: www.prweb.com

INDIGO Biosciences, the recognized industry-leader in Nuclear Receptor research, and Bertin Pharma have announced the completion of a European distribution agreement. Over 40 product references for studying nuclear receptors are now available for European researchers doing their work in drug discovery and toxicology. These innovative tools are used for profiling compounds in research areas such as metabolic disorders, cardiovascular disease, cancer, obesity, and even endocrinology. These all-inclusive, cell-based, and robust kits reduce time, cost, and risk in the drug discovery process by producing easy-to-analyze, accurate results in a fraction of the time of most other kits available. Bertin Pharma is one of the major European players for the supply of reagents and assay kits dedicated to research and development for the pharmaceutical, cosmetic, and food industries. Bertin Pharma has marketed biological reagent ranges for over 25 years. Its long R&D experience combined with its international distributor channels enable Bertin Pharma to deliver life sciences tools on time and to support customers throughout their experimentation. With the addition of INDIGO's portfolio of Nuclear Receptor Assay kits, Bertin Pharma completes it existing ranges of biomarker assays applied to expertise areas including metabolic syndrome, hypertension, and oncology. "It has been a real honor to be introduced to Fred and his company, and we rapidly found a lot of complementary aspects of our businesses. The Nuclear Receptor Assay range perfectly fit with our customers' needs, and will empower our commercial activity." Patrick Vitaux, Bioreagent Department Manager, Bertin Pharma "We are pleased to have reached an agreement with Bertin Pharma to expand our distribution network in Europe. We look forward to working with Patrick and his team to bring INDIGO's assay portfolio to their customers throughout the region." Fred Marroni, CEO, INDIGO Biosciences About INDIGO Biosciences, Inc. INDIGO Biosciences has established itself as an industry-leading provider of both products and services focused on nuclear receptors. INDIGO offers both screening services and assay kits for the pharmaceutical, biotechnology, agri-business, nutriceutical industries, as well as government research agencies and academic researchers. For more information on INDIGO’s products or services, please visit indigobiosciences.com


MONTIGNY-LE-BRETONNEUX, France--(BUSINESS WIRE)--Over 40 product references to assay nuclear receptors are now available for European researchers during their work in drug discovery and toxicology. These innovative tools are used for profiling compounds in research areas such as metabolic disorders, cardiovascular disease, or even endocrinology. Innovative products to reduce time, cost and risk in drug discovery process INDIGO Biosciences, leader in Nuclear Receptor Research, provides the world’s largest portfolio of Nuclear Receptor Assay kits using luciferase reporter technology. Those kits are all-inclusive, cell-based, robust, and ready to use for either screening small numbers of test compounds or HTS application. With a fast-growing business in the USA, INDIGO Biosciences wishes to benefit from increased European exposure to capture new market shares. Bertin Pharma is one of the major European players for the supply of reagents and assay kits dedicated to the research and development for the pharmaceutical, cosmetic and food industries. Bertin Pharma has marketed biological reagent ranges for over 25 years. Its long R&D experience combined with its International distributor channels enable to deliver life science tools on time and to support customers throughout their experimentation. Bertin Pharma completes, with this new range of Nuclear Receptor Assay kits, its existing ranges of biomarker assays applied to his expertise areas that are metabolic syndrome, hypertension or even oncology. “It has been a real honor to be introduced to Fred and his company and we rapidly found a lot of complementarity in our business. The Nuclear Assay range perfectly fit with our customer’s needs, and will empower our commercial activity.” Said Patrick Vitaux, Bioreagent Dpt Manager – Bertin Pharma “We are pleased to have reached an agreement with Bertin Pharma to expand our distribution network in Europe. We look forward to working with Patrick and his team to bring INDIGO’s assay portfolio to their customers throughout the region.” Fred Marroni, CEO – INDIGO Biosciences


MONTIGNY-LE-BRETONNEUX, France--(BUSINESS WIRE)--INDIGO Biosciences, reconnu comme l’acteur majeur de la recherche en récepteurs nucléaires, propose la plus large gamme de trousses de dosage de récepteurs nucléaires. Ces kits, robustes et performants, sont prêt à l’emploi et disponibles sous divers formats (3x 32, 96, et 384 puits) aussi bien pour réaliser le criblage de quelques molécules à un criblage à haut débit. INDIGO Biosciences connaît une croissance exponentielle aux Etats Unis et souhaite profiter de la notoriété et du réseau de Bertin Pharma pour augmenter sa visibilité et conquérir de nouvelles parts de marché. Bertin Pharma est, depuis plus de 25 ans, l’un des principaux fournisseurs européens de réactifs de laboratoire et trousses de dosage destinés à la recherche pharmaceutique, cosmétique ou nutraceutique. Sa longue expérience en tant que distributeur combiné à son réseau de distribution éprouvé lui permettent de livrer rapidement l’ensemble de ses produits et de conseiller ses clients tout au long de leur recherche. INDIGO Biosciences, Inc. a été créé en 2005 à State College, Pennsylvanie. INDIGO est une société de biosciences qui propose des produits et services spécialisés dans les récepteurs nucléaires et destinés à l’industrie pharmaceutique, biotech, environnementale et nutraceutique. INDIGO fournit des services de criblage à haute valeur ajoutée et des trousses de dosage pour la recherche en “drug discovery” et toxicologie. Forte de plus de 20 ans d'expérience dans le développement et la validation de biomarqueurs endogènes et exogènes, Bertin Pharma a développé plus de 150 dosages. Son offre complète couvre nombre de domaines thérapeutiques tels que l'hypertension, le diabète, l'obésité, la psychopharmacologie, l'inflammation, l'hormone de croissance, l'oncologie, les allergies, etc. Bertin Pharma bénéficie d'une clientèle fidèle et prestigieuse: Big & Mid Pharma, sociétés de biotechnologie et aussi des laboratoires de recherche publics. Pour en savoir plus : www.bertinpharma.com. Ses 500 ingénieurs et scientifiques de haut niveau lui permettent d’intervenir notamment dans les secteurs de l’énergie et l’environnement, la défense et la sécurité, la pharmacie et les sciences du vivant ou encore l’aérospatial.

Loading Bertin Pharma collaborators
Loading Bertin Pharma collaborators